{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T18:30:59Z","timestamp":1763058659216,"version":"3.37.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00520-022-06823-y","type":"journal-article","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T00:03:06Z","timestamp":1642118586000},"page":"3761-3772","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical and pharmacoeconomic impact of subgroup analysis in onco-hematological patients"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7342-9495","authenticated-orcid":false,"given":"Manuel David","family":"Gil-Sierra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"del Pilar Brice\u00f1o-Casado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"S\u00e1nchez-Hidalgo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"key":"6823_CR1","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMsr077003","volume":"357","author":"R Wang","year":"2007","unstructured":"Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM (2007) Statistics in medicine\u2013reporting of subgroup analyses in clinical trials. N Engl J Med 357:2189\u20132194. https:\/\/doi.org\/10.1056\/NEJMsr077003","journal-title":"N Engl J Med"},{"issue":"3","key":"6823_CR2","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/ehf2.12093","volume":"3","author":"A Vidic","year":"2016","unstructured":"Vidic A, Chibnall JT, Goparaju N, Hauptman PJ (2016) Subgroup analyses of randomized clinical trials in heart failure: facts and numbers. ESC Heart Fail 3(3):152\u2013157. https:\/\/doi.org\/10.1002\/ehf2.12093","journal-title":"ESC Heart Fail"},{"issue":"2","key":"6823_CR3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jamaoncol.2020.6989","volume":"7","author":"MD Gil-Sierra","year":"2021","unstructured":"Gil-Sierra MD, S\u00e1nchez-Hidalgo M, Alarc\u00f3n de la Lastra-Romero C (2021) Clinical decision-making about neoadjuvant nivolumab plus ipilimumab. JAMA Oncol 7(2):309\u2013309. https:\/\/doi.org\/10.1001\/jamaoncol.2020.6989","journal-title":"JAMA Oncol"},{"key":"6823_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1001\/jama.2013.285063","volume":"311","author":"X Sun","year":"2014","unstructured":"Sun X, Ioannidis JPA, Agoritsas T, Alba AC, Guyatt G (2014) How to use a subgroup analysis: users\u2019 guide to the medical literature. JAMA 311:405\u2013411. https:\/\/doi.org\/10.1001\/jama.2013.285063","journal-title":"JAMA"},{"key":"6823_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3310\/hta5330","volume":"5","author":"S Brookes","year":"2001","unstructured":"Brookes S, Whitley E, Peters T, Mulheran P, Egger M, Davey SG (2001) Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess 5:56. https:\/\/doi.org\/10.3310\/hta5330","journal-title":"Health Technol Assess"},{"issue":"4","key":"6823_CR6","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1001\/jamainternmed.2016.9125","volume":"177","author":"JD Wallach","year":"2017","unstructured":"Wallach JD, Sullivan PG, Trepanowski JF, Sainani KL, Steyerberg EW, Ioannidis JPA (2017) Evaluation of evidence of statistical support and corroboration of subgroup claims in randomized clinical trials. JAMA Intern Med 177(4):554\u2013560. https:\/\/doi.org\/10.1001\/jamainternmed.2016.9125","journal-title":"JAMA Intern Med"},{"key":"6823_CR7","doi-asserted-by":"publisher","unstructured":"Altman DG, Matthews JN (1996) Statistics notes. Interaction 1: heterogeneity of effects. BMJ 313(7055):486. https:\/\/doi.org\/10.1136\/bmj.313.7055.486","DOI":"10.1136\/bmj.313.7055.486"},{"issue":"7061","key":"6823_CR8","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1136\/bmj.313.7061.862","volume":"313","author":"JN Matthews","year":"1996","unstructured":"Matthews JN, Altman DG (1996) Interaction 3: How to examine heterogeneity. BMJ 313(7061):862. https:\/\/doi.org\/10.1136\/bmj.313.7061.862","journal-title":"BMJ"},{"key":"6823_CR9","doi-asserted-by":"publisher","unstructured":"Matthews JN, Altman DG (1996) Statistics notes. Interaction 2: compare effect sizes not P values. BMJ 313(7060):808. https:\/\/doi.org\/10.1136\/bmj.313.7060.808","DOI":"10.1136\/bmj.313.7060.808"},{"issue":"5","key":"6823_CR10","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1097\/JTO.0b013e3181d9009e","volume":"5","author":"H Barraclough","year":"2010","unstructured":"Barraclough H, Govindan R (2010) Biostatistics primer: what a clinician ought to know: subgroup analyses. J Thorac Oncol 5(5):741\u2013746. https:\/\/doi.org\/10.1097\/JTO.0b013e3181d9009e","journal-title":"J Thorac Oncol"},{"issue":"7139","key":"6823_CR11","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1136\/bmj.316.7139.1236","volume":"316","author":"TV Perneger","year":"1998","unstructured":"Perneger TV (1998) What\u2019s wrong with Bonferroni adjustments. BMJ 316(7139):1236\u20131238. https:\/\/doi.org\/10.1136\/bmj.316.7139.1236","journal-title":"BMJ"},{"key":"6823_CR12","unstructured":"European Medicines Agency (1996) 1996 ICH topic E3: structure and content of clinical study reports. Note for guidance on structure and content of clinical study reports (CPMP\/ICH\/137\/95) [cited February 21, 2019]. Available in: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e-3-structure-content-clinical-study-reports-step-5_en.pdf"},{"issue":"15","key":"6823_CR13","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1200\/JCO.2014.59.8862","volume":"33","author":"S Zhang","year":"2015","unstructured":"Zhang S, Liang F, Li W, Hu X (2015) Subgroup analyses in reporting of phase III clinical trials in solid tumors. J Clin Oncol 33(15):1697\u20131702. https:\/\/doi.org\/10.1200\/JCO.2014.59.8862","journal-title":"J Clin Oncol"},{"key":"6823_CR14","doi-asserted-by":"publisher","unstructured":"B\u00e1ez-Guti\u00e9rrez N, Rodr\u00edguez-Ramallo H, Flores-Moreno S, Abdel-Kader ML (2020) Subgroup analysis in haematologic malignancies phase III clinical trials: a systematic review. Br J ClinPharmacol.\u00a0https:\/\/doi.org\/10.1111\/bcp.14689","DOI":"10.1111\/bcp.14689"},{"issue":"3","key":"6823_CR15","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/jcpt.13102","volume":"45","author":"MD Gil-Sierra","year":"2020","unstructured":"Gil-Sierra MD, F\u00e9nix-Caballero S, Abdel Kader-Martin L, Fraga-Fuentes MD, S\u00e1nchez-Hidalgo M, Alarc\u00f3n de la Lastra-Romero C et al (2020) Checklist for clinical applicability of subgroup analysis. J Clin Pharm Ther 45(3):530\u2013538. https:\/\/doi.org\/10.1111\/jcpt.13102","journal-title":"J Clin Pharm Ther"},{"issue":"15","key":"6823_CR16","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN (2018) Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 378(15):1408\u20131418. https:\/\/doi.org\/10.1056\/NEJMoa1715546","journal-title":"N Engl J Med"},{"issue":"4","key":"6823_CR17","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S1470-2045(18)30898-2","volume":"20","author":"B Tombal","year":"2019","unstructured":"Tombal B, Saad F, Penson D, Hussain M, Sternberg CN, Morlock R et al (2019) Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 20(4):556\u2013569. https:\/\/doi.org\/10.1016\/S1470-2045(18)30898-2","journal-title":"Lancet Oncol"},{"issue":"26","key":"6823_CR18","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","volume":"378","author":"M Hussain","year":"2018","unstructured":"Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U et al (2018) Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 378(26):2465\u20132474. https:\/\/doi.org\/10.1056\/NEJMoa1800536","journal-title":"N Engl J Med"},{"issue":"1","key":"6823_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/ejh.13407","volume":"105","author":"MD Gil-Sierra","year":"2020","unstructured":"Gil-Sierra MD, Gimeno-Ballester V, Fenix-Caballero S, Alegre-Del Rey EJ (2020) Network meta-analysis of first-line treatments in transplant-ineligible multiple myeloma patients. Eur J Haematol 105(1):56\u201365. https:\/\/doi.org\/10.1111\/ejh.13407","journal-title":"Eur J Haematol"},{"key":"6823_CR20","doi-asserted-by":"publisher","unstructured":"Gil-Sierra MD, Gimeno-Ballester V, Brice\u00f1o-Casado MDP, Sanchez-Hidalgo M, Alarcon de la Lastra-Romero C, Fenix-Caballero S, Rios-Sanchez E, Diaz-Navarro J, Martinez-Diaz C, Borrero-Rubio JM, Alegre-Del Rey EJ. 2019 Network meta-analysis of first-line antiangiogenic drugs in advanced renal cell carcinoma. Abstract presented in 23rd European Association of Hospital Pharmacists Congress; 2019 March 27\u201329; Barcelona. Available in: https:\/\/www.eahp.eu\/sites\/default\/files\/abstract_book_-_bar19.pdf. https:\/\/doi.org\/10.1136\/ejhpharm-2019-eahpconf.51","DOI":"10.1136\/ejhpharm-2019-eahpconf.51"},{"issue":"7060","key":"6823_CR21","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/bmj.313.7060.808","volume":"313","author":"JNS Matthews","year":"1996","unstructured":"Matthews JNS, Altman DG (1996) Statistics Notes: Interaction 2: compare effect sizes not P values. BMJ 313(7060):808. https:\/\/doi.org\/10.1136\/bmj.313.7060.808","journal-title":"BMJ"},{"key":"6823_CR22","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F et al (2018) Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer. N Engl J Med 378:2078\u20132092. https:\/\/doi.org\/10.1056\/NEJMoa1801005","journal-title":"N Engl J Med"},{"issue":"11","key":"6823_CR23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1808567","volume":"379","author":"MD Gil-Sierra","year":"2018","unstructured":"Gil-Sierra MD, Fenix-Caballero S, Alegre-del RE (2018) Pembrolizumab plus chemotherapy in lung cancer. N Engl J Med 379(11):e18. https:\/\/doi.org\/10.1056\/NEJMc1808567","journal-title":"N Engl J Med"},{"issue":"1","key":"6823_CR24","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge","year":"2019","unstructured":"Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X et al (2019) The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol 6(1):116\u2013124. https:\/\/doi.org\/10.1001\/jamaoncol.2019.4782","journal-title":"JAMA Oncol"},{"issue":"7","key":"6823_CR25","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/jamaoncol.2020.1516","volume":"6","author":"MD Gil-Sierra","year":"2020","unstructured":"Gil-Sierra MD, Brice\u00f1o-Casado MDP, F\u00e9nix-Caballero S (2020) Analysis of overall survival benefit of abemaciclib plus fulvestrant in hormone receptor-positive, ERBB2-negative breast cancer. JAMA Oncol 6(7):1122. https:\/\/doi.org\/10.1001\/jamaoncol.2020.1516","journal-title":"JAMA Oncol"},{"issue":"22","key":"6823_CR26","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N et al (2019) Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 380(22):2104\u20132115. https:\/\/doi.org\/10.1056\/NEJMoa1817249","journal-title":"N Engl J Med"},{"issue":"6","key":"6823_CR27","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S et al (2018) Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med 378(6):518\u2013528. https:\/\/doi.org\/10.1056\/NEJMoa1714678","journal-title":"N Engl J Med"},{"issue":"10218","key":"6823_CR28","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","volume":"395","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A et al (2020) Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet 395(10218):132\u2013141. https:\/\/doi.org\/10.1016\/S0140-6736(19)32956-3","journal-title":"Lancet"},{"issue":"14","key":"6823_CR29","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J-J, Cowey CL et al (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377(14):1345\u20131356. https:\/\/doi.org\/10.1056\/NEJMoa1709684","journal-title":"N Engl J Med"},{"issue":"25","key":"6823_CR30","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1056\/NEJMc1714339","volume":"377","author":"EJ Alegre-del-Rey","year":"2017","unstructured":"Alegre-del-Rey EJ, de la Nogal FB, Brice\u00f1o-Casado P (2017) Nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377(25):2503. https:\/\/doi.org\/10.1056\/NEJMc1714339","journal-title":"N Engl J Med"},{"issue":"10","key":"6823_CR31","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s40261-018-0690-9","volume":"38","author":"FS Mennini","year":"2018","unstructured":"Mennini FS, Bini C, Marcellusi A, Del Vecchio M (2018) Cost estimate of immune-related adverse reactions associated with innovative treatments of metastatic melanoma. Clin Drug Investig 38(10):967\u2013976. https:\/\/doi.org\/10.1007\/s40261-018-0690-9","journal-title":"Clin Drug Investig"},{"key":"6823_CR32","unstructured":"Ficha t\u00e9cnica Yervoy 5 mg\/ml concentrado para soluci\u00f3n para perfusi\u00f3n [Internet]. 2019 [cited July 2020, 26]. Available in: https:\/\/cima.aemps.es\/cima\/publico\/lista.html"},{"key":"6823_CR33","unstructured":"Organization WH. Technical report: pricing of cancer medicines and its impacts: a comprehensive technical report for the World Health Assembly Resolution 70.12: operative paragraph 2.9 on pricing approaches and their impacts on availability and affordability of medicines for the prevention and treatment of cancer [Internet]. 2018 [cited 2019 August 11]. Available in: https:\/\/apps.who.int\/iris\/handle\/10665\/277190"},{"issue":"8","key":"6823_CR34","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen Y-H, Carducci M, Liu G, Jarrard DF, Eisenberger M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373(8):737\u2013746. https:\/\/doi.org\/10.1056\/NEJMoa1503747","journal-title":"N Engl J Med"},{"issue":"11","key":"6823_CR35","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM et al (2018) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 36(11):1080\u20131087. https:\/\/doi.org\/10.1200\/JCO.2017.75.3657","journal-title":"J Clin Oncol"},{"issue":"2","key":"6823_CR36","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","volume":"14","author":"G Gravis","year":"2013","unstructured":"Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B et al (2013) Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 14(2):149\u2013158. https:\/\/doi.org\/10.1016\/S1470-2045(12)70560-0","journal-title":"Lancet Oncol"},{"issue":"12","key":"6823_CR37","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","volume":"30","author":"NW Clarke","year":"2019","unstructured":"Clarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G et al (2019) Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol 30(12):1992\u20132003. https:\/\/doi.org\/10.1093\/annonc\/mdz396","journal-title":"Ann Oncol"},{"issue":"7","key":"6823_CR38","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1177\/10781552211037322","volume":"27","author":"MD Gil-Sierra","year":"2021","unstructured":"Gil-Sierra MD, Alegre-Del Rey EJ, Alarcon de la Lastra-Romero C, S\u00e1nchez-Hidalgo M (2021) Use of docetaxel in low- and high-burden metastatic hormone-sensitive prostate cancer: a systematic review and assessment of subgroup analyses. J Oncol Pharm Pract 27(7):1743\u20131750","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"6823_CR39","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R et al (2019) Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 381(1):13\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1903307","journal-title":"N Engl J Med"},{"issue":"5","key":"6823_CR40","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY et al (2019) Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 20(5):686\u2013700. https:\/\/doi.org\/10.1016\/S1470-2045(19)30082-8","journal-title":"Lancet Oncol"},{"issue":"20","key":"6823_CR41","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner NC, Slamon DJ, Ro J, Bondarenko I, Im S, Masuda M et al (2018) Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med 379(20):1926\u20131936. https:\/\/doi.org\/10.1056\/NEJMoa1810527","journal-title":"N Engl J Med"},{"issue":"24","key":"6823_CR42","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA et al (2018) Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 36(24):2465\u20132472. https:\/\/doi.org\/10.1200\/JCO.2018.78.9909","journal-title":"J Clin Oncol"},{"issue":"19","key":"6823_CR43","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823\u20131833. https:\/\/doi.org\/10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"key":"6823_CR44","doi-asserted-by":"publisher","unstructured":"Gil-Sierra MD, Fenix-Caballero S, Sanchez-Hidalgo M, Alarcon de la Lastra Romero C, Brice\u00f1o-Casado MDP, Rios-Sanchez E, Diaz-Navarro J, Martinez-Diaz C, Camean-Castillo M, Borrero-Rubio JM, Alegre-Del Rey E. 2019 Indirect comparison of pembrolizumab plus chemotherapy versus pembrolizumab in lung cancer. Abstract presented in 23rd European Association of Hospital Pharmacists Congress; 2019 March 27\u201329; Barcelona. Available in: https:\/\/www.eahp.eu\/sites\/default\/files\/abstract_book_-_bar19.pdf. https:\/\/doi.org\/10.1136\/ejhpharm-2019-eahpconf.50","DOI":"10.1136\/ejhpharm-2019-eahpconf.50"},{"issue":"7382","key":"6823_CR45","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","volume":"326","author":"DG Altman","year":"2003","unstructured":"Altman DG, Bland JM (2003) Interaction revisited: the difference between two estimates. BMJ 326(7382):219. https:\/\/doi.org\/10.1136\/bmj.326.7382.219","journal-title":"BMJ"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-06823-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-06823-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-06823-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T07:11:00Z","timestamp":1648019460000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-06823-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["6823"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-06823-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2022,1,13]]},"assertion":[{"value":"18 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Gil-Sierra Manuel David: membership of an advisory board (consultation fees), lecture for Janssen Pharmaceutica and Pfizer (reimbursement for attending symposia) of cancer drugs. The rest of the authors have no conflict of interest to declare.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}